PMID- 34072123
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210710
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 10
IP  - 6
DP  - 2021 May 27
TI  - Cardamonin Attenuates Inflammation and Oxidative Stress in 
      Interleukin-1beta-Stimulated Osteoarthritis Chondrocyte through the Nrf2 Pathway.
LID - 10.3390/antiox10060862 [doi]
LID - 862
AB  - Osteoarthritis (OA) is a chronic degenerative joint disease characterized by the 
      deterioration of articular cartilage. The progression of OA leads to an increase 
      in inflammatory mediators in the joints, thereby promoting the destruction of the 
      cartilage matrix. Recent studies have reported on the anti-inflammatory and 
      antioxidant properties of cardamonin, which also appears to interact with 
      cellular targets, such as nuclear erythroid 2-related factor 2 (Nrf2), 
      extracellular signal-regulated kinase (ERK), and mammalian target of rapamycin 
      (mTOR) during the progression of tumors. To date, few studies have investigated 
      the effects of cardamonin on chondrocyte inflammation. In the current study, we 
      determined that treating interleukin-1 beta (IL-1beta-stimulated chondrocyte cells) 
      with cardamonin significantly reduced the release of nitric oxide (NO) and 
      prostaglandin E2 (PGE2) and significantly inhibited the expression of 
      pro-inflammatory proteins, including inducible nitric oxide synthase (iNOS) and 
      cyclooxygenase 2 (COX2). Cardamonin was also shown to: (1) inhibit the activation 
      and production of matrix metalloproteinases (MMPs), (2) suppress the nuclear 
      factor-kappaB (NF-kappaB) signaling pathway, (3) suppress the expression of toll-like 
      receptor proteins, (4) activate the Nrf2 signaling pathway, and (5) increase the 
      levels of antioxidant proteins heme oxygenase-1 (HO-1) and NAD(P)H:quinone 
      oxidoreductase 1 (NQO1). The increase in antioxidant proteins led to 
      corresponding antioxidant effects (which were abolished by Nrf2 siRNA). Our 
      findings identify cardamonin as a candidate Nrf2 activator for the treatment and 
      prevention of OA related to inflammation and oxidative stress.
FAU - Peng, Yi-Jen
AU  - Peng YJ
AUID- ORCID: 0000-0003-4630-2103
AD  - Department of Pathology, National Defense Medical Center, Tri-Service General 
      Hospital, Taipei 114, Taiwan.
FAU - Lu, Jeng-Wei
AU  - Lu JW
AUID- ORCID: 0000-0003-2128-2046
AD  - Department of Biological Sciences, National University of Singapore, Singapore 
      117543, Singapore.
FAU - Lee, Chian-Her
AU  - Lee CH
AD  - Department of Orthopedics, School of Medicine, College of Medicine, Taipei 
      Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan.
FAU - Lee, Herng-Sheng
AU  - Lee HS
AD  - Laboratory Medicine, Department of Pathology, Kaohsiung Veterans General 
      Hospital, Kaohsiung 813, Taiwan.
FAU - Chu, You-Hsiang
AU  - Chu YH
AD  - National Defense Medical Center, Graduate Institute of Life Sciences, Taipei 114, 
      Taiwan.
FAU - Ho, Yi-Jung
AU  - Ho YJ
AD  - National Defense Medical Center, Graduate Institute of Life Sciences, Taipei 114, 
      Taiwan.
AD  - National Defense Medical Center, School of Pharmacy, Taipei 114, Taiwan.
FAU - Liu, Feng-Cheng
AU  - Liu FC
AD  - Department of Medicine, Rheumatology/Immunology and Allergy, National Defense 
      Medical Center, Tri-Service General Hospital, Taipei 114, Taiwan.
FAU - Huang, Chun-Jung
AU  - Huang CJ
AD  - Department of Pathology, National Defense Medical Center, Tri-Service General 
      Hospital, Taipei 114, Taiwan.
FAU - Wu, Chia-Chun
AU  - Wu CC
AD  - Department of Orthopedics, National Defense Medical Center, Tri-Service General 
      Hospital, Taipei 114, Taiwan.
FAU - Wang, Chih-Chien
AU  - Wang CC
AUID- ORCID: 0000-0003-3709-3848
AD  - Department of Orthopedics, National Defense Medical Center, Tri-Service General 
      Hospital, Taipei 114, Taiwan.
LA  - eng
GR  - MOST 107-2314-B-038-088/Ministry of Science and Technology/
GR  - MOST108-2314-B-038-082/Ministry of Science and Technology/
GR  - ATSGH-C107-211/National Defense Medical Center/
GR  - TSGH-C107-081/National Defense Medical Center/
GR  - TSGH-108-089/National Defense Medical Center/
GR  - TSGH-C108-113/National Defense Medical Center/
GR  - TSGH-D-10902/National Defense Medical Center/
GR  - TSGH-E-110232/National Defense Medical Center/
GR  - MAB-106-006/Ministry of National Defense-Medical Affairs Bureau/
PT  - Journal Article
DEP - 20210527
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC8227809
OTO - NOTNLM
OT  - cardamonin
OT  - chondrocyte
OT  - interleukin-1 beta
OT  - osteoarthritis
OT  - oxidative stress
COIS- The authors declare no conflict of interest.
EDAT- 2021/06/03 06:00
MHDA- 2021/06/03 06:01
PMCR- 2021/05/27
CRDT- 2021/06/02 01:34
PHST- 2021/05/01 00:00 [received]
PHST- 2021/05/20 00:00 [revised]
PHST- 2021/05/25 00:00 [accepted]
PHST- 2021/06/02 01:34 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/03 06:01 [medline]
PHST- 2021/05/27 00:00 [pmc-release]
AID - antiox10060862 [pii]
AID - antioxidants-10-00862 [pii]
AID - 10.3390/antiox10060862 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2021 May 27;10(6):862. doi: 10.3390/antiox10060862.